A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans

Beth Israel Lahey Health

Status: Completed

Conditions: Intestinal FDG Uptake

Treatments: Drug: Rifaximin

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01542541

2010P000101

Details and patient eligibility

About

Patients who undergo PET-CT scans to look for cancer are given an intravenous contrast (FDG) that is taken-up by active cells such as cancer cells. This contrast can then be seen in the body using the PET-CT scanner. However, cells in the colon also take up the FDG, and can produce "false positive" signals from the colon. Our hypothesis is that much of this signal comes from bacteria that are present in high concentrations in the colon. If this is the case, using an antibiotic to suppress the activity of bacteria may improve the ability of PET-CT to distinguish abnormal cells from normal cells in the colon.

Enrollment: 68 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients undergoing clinically-indicated PET-CT scan for non-GI lymphoma

Exclusion criteria

• Patients with known Inflammatory Bowel Disease
• Patients with known colon cancer

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

68 participants in 2 patient groups

Rifaximin

Experimental group

Treatment:

Drug: Rifaximin

Control

No Intervention group

Description:

Randomly-selected matched PET-CT scans performed on same day as intervention group.